EyePoint (EYPT) Current Leases (2019)
EyePoint (EYPT) posted Current Leases of $481000.0 for Q4 2019, up 4.34% sequentially from $461000.0 in Q3 2019.
Powered by 
Analysis
EyePoint (EYPT) Current Leases (2019) Analysis & Trends
EyePoint has reported Current Leases for 1 years, with the latest figure at $481000.0 in Q4 2019.
- Quarterly Current Leases changed N/A year-over-year to $481000.0 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $481000.0 (changed N/A YoY) and the FY2019 annual result came in at $481000.0, changed N/A from the prior year.
- Current Leases rose to $481000.0 in Q4 2019 per EYPT's latest filing, from $461000.0 in the prior quarter.
- Over five years, Current Leases peaked at $481000.0 in Q4 2019 and troughed at $417000.0 in Q1 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 11.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 16.75 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 21.95 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.27 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | 481,000.00 |
| Sep 30, 2019 | 461,000.00 |
| Jun 30, 2019 | 441,000.00 |
| Mar 31, 2019 | 417,000.00 |